356 related articles for article (PubMed ID: 36795198)
1. Nanomedicine in therapeutic warfront against estrogen receptor-positive breast cancer.
Aalhate M; Mahajan S; Singh H; Guru SK; Singh PK
Drug Deliv Transl Res; 2023 Jun; 13(6):1621-1653. PubMed ID: 36795198
[TBL] [Abstract][Full Text] [Related]
2. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
Brufsky AM; Dickler MN
Oncologist; 2018 May; 23(5):528-539. PubMed ID: 29352052
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194
[TBL] [Abstract][Full Text] [Related]
5. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.
Miranda F; Prazeres H; Mendes F; Martins D; Schmitt F
Mol Biol Rep; 2022 Jan; 49(1):717-733. PubMed ID: 34739691
[TBL] [Abstract][Full Text] [Related]
6. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
[TBL] [Abstract][Full Text] [Related]
7. Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer.
Andrahennadi S; Sami A; Manna M; Pauls M; Ahmed S
Curr Oncol; 2021 May; 28(3):1803-1822. PubMed ID: 34064867
[No Abstract] [Full Text] [Related]
8. Folic Acid Conjugated Nanocarriers for Efficient Targetability and Promising Anticancer Efficacy for Treatment of Breast Cancer: A Review of Recent Updates.
Choudhury H; Pandey M; Wen LP; Cien LK; Xin H; Yee ANJ; Lee NJ; Gorain B; Amin MCIM; Pichika MR
Curr Pharm Des; 2020; 26(42):5365-5379. PubMed ID: 32693762
[TBL] [Abstract][Full Text] [Related]
9. A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.
Clusan L; Le Goff P; Flouriot G; Pakdel F
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451133
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
11. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
13. Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.
Xia S; Lin Q
Technol Cancer Res Treat; 2022; 21():15330338221090351. PubMed ID: 35450488
[TBL] [Abstract][Full Text] [Related]
14. The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies.
Yang F; He Q; Dai X; Zhang X; Song D
Front Pharmacol; 2023; 14():1143102. PubMed ID: 36909177
[TBL] [Abstract][Full Text] [Related]
15. NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer.
Bhat R; Thangavel H; Abdulkareem NM; Vasaikar S; De Angelis C; Bae L; Cataldo ML; Nanda S; Fu X; Zhang B; Schiff R; Trivedi MV
Sci Rep; 2022 Feb; 12(1):1972. PubMed ID: 35121782
[TBL] [Abstract][Full Text] [Related]
16. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Patel HK; Bihani T
Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 inhibitors in breast cancer - from
Saleh L; Wilson C; Holen I
Acta Oncol; 2020 Feb; 59(2):219-232. PubMed ID: 31671026
[No Abstract] [Full Text] [Related]
18. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
20. A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.
Asghari A; Wall K; Gill M; Vecchio ND; Allahbakhsh F; Wu J; Deng N; Zheng WJ; Wu H; Umetani M; Maroufy V
Oncotarget; 2022; 13():600-613. PubMed ID: 35401937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]